.jpeg)
2026-08-20 03:12:46
Dabrafenib (brand name TAFINLAR) is a highly selective oral BRAF kinase inhibitor, most commonly used in combination with the MEK inhibitor trametinib for the treatment of BRAF V600–mutant solid tumors including melanoma, non-small cell lung cancer, anaplastic thyroid cancer, and pediatric low-grade glioma. This article provides a structured overview of its approved indications, the characteristic pyrexia syndrome and other adverse effects, grade-based management strategies, dose-reduction and discontinuation protocols, and special-population safety considerations to support comprehensive treatment management.
2026-08-20 03:03:58
Adagrasib (brand name Krazati) is the second approved highly selective, covalent KRAS G12C inhibitor for patients with KRAS G12C–mutant non-small cell lung cancer and colorectal cancer. This article systematically reviews the drug's adverse-effect profile—centered on gastrointestinal toxicity and hepatotoxicity—and provides structured, grade-based management strategies for diarrhea, liver enzyme elevation, fatigue, QTc prolongation, and hematologic effects, along with dose-modification principles to help patients and clinical teams maintain the optimal balance between efficacy and safety throughout treatment.
2026-08-20 02:55:43
Tepotinib (brand name TEPMETKO) is a highly selective oral MET tyrosine kinase inhibitor approved for adults with metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations. This article provides a structured guide to the standard dosing regimen, proactive management of peripheral edema and other adverse effects, dose-reduction and discontinuation criteria, risk assessment in special populations, drug-interaction considerations, and a recommended monitoring schedule to support safe and effective targeted therapy.
2026-08-20 02:49:09
Valganciclovir (brand name Valcyte) is the cornerstone oral antiviral agent for the prevention and treatment of cytomegalovirus (CMV) infection following solid organ transplantation. This article provides a structured overview of prophylactic regimens across kidney, heart, and kidney-pancreas transplantation, monitoring and management of myelosuppression, renal function–guided dose adjustments, strategies for addressing antiviral resistance, and practical tips for long-term adherence.
2026-08-19 06:59:25
Tivozanib is an oral VEGFR tyrosine kinase inhibitor used in advanced renal cell carcinoma, administered at 1.34 mg once daily in a 21-days-on, 7-days-off, 28-day cycle. This article covers standard dosing, dose modification for adverse events, and reduced dosing for moderate hepatic impairment.
2026-08-19 06:01:50
Anagrelide (Anagrelide) is a platelet-reducing agent widely used in essential thrombocythemia. Prolonged use may involve cardiovascular, gastrointestinal, and neurological adverse effects. This article provides a systematic overview of its safety profile and key points for long-term medication management.
2026-08-19 04:54:11
Resmetirom is approved for adults with non-cirrhotic NASH/MASH and moderate-to-severe liver fibrosis (F2–F3). It is not an antiviral agent for hepatitis B virus (HBV) and is not indicated for HBV-related cirrhosis. This article clarifies its mechanism of action and precise indication boundaries.
2026-08-19 04:40:21
Vemurafenib is an oral small-molecule BRAF kinase inhibitor designed to selectively target BRAF V600E and related mutations. This article explores its molecular mechanism, the essential role of BRAF genetic testing, and its positioning within precision oncology.
2026-08-19 04:31:49
Anagrelide and hydroxyurea are both widely used cytoreductive agents for essential thrombocythemia (ET). They differ in mechanism of action, vascular event prevention, adverse effect profiles, and long-term therapeutic positioning. This article provides a comprehensive comparison to guide individualized treatment decisions.
2026-08-18 04:30:05
SCEMBLIX (asciminib) is the first BCR-ABL1 myristoyl pocket allosteric inhibitor for chronic myeloid leukemia. This guide covers common side effects, dosing in hepatic/renal impairment, cardiovascular monitoring, drug interactions, and pregnancy risk.
2026-08-18 03:33:32
Sabril (vigabatrin) is an anti-seizure drug that irreversibly inhibits GABA transaminase to raise brain GABA levels. It is a key option for infantile spasms and refractory partial seizures, but carries a risk of permanent visual field loss requiring strict evaluation and regular ophthalmologic monitoring.
2026-08-18 03:25:17
In August 2026, the FDA approved Tauklarify (florquinitau F-18 injection, MK-6240), a radioactive diagnostic agent for PET imaging of tau neurofibrillary tangles in adult patients with cognitive impairment being evaluated for Alzheimer's disease.
